MD
Insider
Michael H. Davidson
Chief Executive OfficerMichael H. Davidson (Chief Executive Officer) filed 4 Form 4 reports in the trailing twelve months (1 purchase, 3 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $14.8M of NAMS (443,707 sh × $33.25, as filed), executed Mar 2. The median gap between execution and disclosure was 1 day.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
purchases not yet priced
Delay-adjustediThe same average, entered at disclosure dates
–
purchases not yet priced
Filings, ttm
4
1 buys · 3 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$25.9M
shares × price, as filed
Last traded
Sep 14
Filed Sep 15
Median ADV $32.2M across their filed names
100% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.
Open performance→Volume by month
Buys $226K
Sells $26.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
4 filings
Sector per market data · by filing · past 12 months
Most traded names
NAMSRecent filings
NAMSPURCHASE
NewAmsterdam Pharma Company N.V.
View filing →
$226K10,000 sh × $22.65
Exec Sep 14
Filed Sep 15 · 4:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. View filing → $14.8M
443,707 sh × $33.25
Exec Mar 2
Filed Mar 2 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. View filing → $10.5M
304,993 sh across 6 lots
Exec Feb 24
Filed Feb 26 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. View filing → $411K
as filed
Exec Jan 7
Filed Jan 9 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. View filing → $277K
as filed
Exec Mar 26 2025
Filed Mar 28 2025 · 5:30 PM ET